The tweet was deleted by the author.
But we saved everything 🙂.
Fulgent Genetics has announced a major update to its FulGenome whole genome sequencing (WGS) solution. The latest version now detects 64 repeat expansions, a significant increase from the previous capability of 20, all consolidated into one streamlined report.
This enhancement is aimed at improving the clinical utility of WGS by providing broader coverage of repeat expansion disorders in a single test. The update positions Fulgent Genetics as a leader in advanced genomic diagnostics as demand grows for comprehensive genetic testing solutions.
View post on X Loading...
Fulgent Genetics recently shared updated Phase 2 data for its FID-007 candidate in combination with cetuximab and announced upcoming plans for a Phase 3 trial at ASCO26, according to a prior disclosure. The company also outlined efforts to increase industry engagement at the APG2026 Exhibit Fair and Strolling Dinner in San Diego, as detailed in a separate event summary. These initiatives reflect a continued expansion of Fulgent's clinical and industry presence.